Research Progress Sample Clauses

Research Progress. 11.1. Research plan preparation The Management Committee will make recommendations to the Steering Committee concerning the Network research plan (including related budgets) for the corning year. This recommendation will be based on demonstrated progress and will include a statement on: i. the continuation or modification of existing Network Research projects; ii. the acceptance of new Network Research projects; and iii. the use of new external financial support from other sources. These recommendations will be sent to the Steering Committee each year as directed by such Committee. 11.2. Annual network meeting or workshop The network will organize an annual meeting among its investigators, members, affiliates, and others, as considered appropriate by the Steering Committee, to share and discuss the results of the research and other activities. SSHRC will be informed of this meeting and retains the right to be represented at it. 11.3. Mid-term and final research report A mid-term research progress report prepared by the Project Director, Project Coordinator and Management Committee will be submitted to the Steering Committee who will submit an approved copy as required by SSHRC. The Network's Final Research Report will be due six months after the end of all Network activities.
AutoNDA by SimpleDocs
Research Progress. Each Party will keep the other Party reasonably informed regarding the progress and results of such Party’s activities under the Joint Research Program, including an annual review of results versus any goals set forth in the Joint Research Plan.
Research Progress. Regular reviews of student performance are mandatory (Graduate e-Calendar, Research Progress Tracking). • The student’s Research Advisory Committee (RAC) consists of the supervisor and two other faculty members, one from the Biochemistry Department and one from another department. The RAC should have appropriate expertise to evaluate progress, and is established within the first semester of study. • The first RAC meeting must be no later than in the third semester, and at least once each following year. Failure to hold annual RAC meetings will be grounds for withdrawal. • The student is responsible to arrange RAC meetings, and submit the evaluation reports signed by the student, RAC members and GPD to the Student Affairs Officer of Biochemistry. • If an evaluation is “unsatisfactory”, the student must have another RAC meeting in 4 – 6 months to address concerns. A second “unsatisfactory” will be grounds for withdrawal. • A failure in one required course and one RAC evaluation will be grounds for withdrawal. • RAC approval is required to submit the X.Xx. thesis, Junior Seminar, Thesis Proposal and Senior Seminar.
Research Progress and Accomplishments (to date in relation to expected milestones and deliverables / outputs)
Research Progress. The meetings organized by Task 25 have established an international forum for ex- change of knowledge and experiences.The spring task meeting in 2008 was organized in Denmark and hosted by the TSO En- xxxxxxx.xx. In the autumn meeting, hosted by ECAR and SEI in Dublin, participating countries presented the national results in a one-day seminar followed by discussions about the final report. Coordination with other relevant activ- ities is an important part of the Task 25 ef- fort.The meetings in 2007 were organized in conjunction with Task 24, Integration of Wind and Hydropower Systems.The system operators of Denmark, Germany, Ireland, Portugal, and the UK have joined the meetings organized thus far. Links be- tween TSO organization working groups at CIGRE and ETSO European Wind In- tegration Study (EWIS project) have been formed, and observers have joined Task 25 meetings in 2008 and 2009. Publication of the work is a key goal of Task 25 co-operative research. In 2007, national case studies presented in a ses- sion organized for the European Wind Energy Conference (EWEC) in Brussels in April 2008.Task 25 work and results were presented at several other key meet- ings in 2008: the CIGRE C6-08 meeting in Berlin, Germany; the Irish Wind Energy Association meeting; a wind integration workshop in Madrid, Spain; the Windpower 2008 conference in Houston,Texas, United States; and the IEEE Power Engineering Society meeting in Pittsburgh, Pennsylvania, United States. Work has begun on a simplified assess- ment of wind integration effort and power system flexibility.The assessment draws on the work done by the Operating Agent for an IEA Secretariat study for the G8 on integrating renewable energy sources. In addition, a paper collecting results on statis- tical methods assessing short-term reserve requirements of wind power from Finland, Sweden, and the United States was pub- lished in Wind Engineering. The Task 25 web site has been estab- lished at xxxx://xxx.xxxxxxx.xxx under Task Web Sites.The public portion of the site contains the Task 25 publications and a bibliography completed in 2008 in conjunction with Task 24 that lists publi- cations related to system integration.The members-only section details the meeting presentations and information relevant to task participants.

Related to Research Progress

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Term The term “

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!